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SCIENCE AND SOCIETY 
Debating a testosterone  
“sex gap” in elite athletes 
T-based policies unfairly exclude some women from competition. 
By Katrina Karkazis1* and Rebecca Jordan-Young2 
Sex dimorphism of testosterone (T) in elite ath-
letes was at the center of a recent case at the 
“Supreme Court of Sport”, the Court of Arbi-
tration for Sport in Switzerland, after teenage 
Indian sprinter Dutee Chand challenged a 
sports policy regulating competition eligibility 
of women with naturally high T. The idea of a 
“sex gap” in T is a cornerstone of this policy 
(1). Policymakers infer that men’s higher T is 
the “one factor [that] makes a decisive differ-
ence” between men’s and women’s athletic 
performances (2) —so they claim that women 
with naturally high T unfairly enjoy a “massive 
androgenic advantage” over other women ath-
letes (2). Yet there’s an emerging scientific de-
bate about whether the sex gap in T applies to 
elite athletes. 
In 2011 and 2012, respectively, the Interna-
tional Association of Athletics Federations 
(IAAF) and the International Olympic Com-
mittee (IOC) adopted controversial policies 
that regulate levels of natural T in women ath-
letes (1, 3). The IAAF policy sets a ceiling of 
10nmol/L for women, which it identifies as 
“within the normal male range”, whereas the 
IOC policy targets levels “within the male 
range” rather than setting a threshold (1, 3). 
Women with high natural T, according to the 
IAAF, have unfair advantage over women with 
lower natural levels (1, p. 12). Unless they are 
androgen resistant, women must lower their T 
in order to continue competing (1), which 
would require surgery or anti-androgens (4). 
Appealing her exclusion under the IAAF 
policy, Chand told the Indian Express “At eve-
ry level of my life…I have competed the way I 
am. I’ve been told the hormonal issue with me 
is natural so that’s why we have decided [to 
appeal]” (5). Her March appeal was the first 
formal challenge to the policy; a decision is 
forthcoming. 
The T policy is the latest attempt to use a 
biological marker to draw a bright line between 
women and men for sex-segregated sports. 
Decades of sex testing of all women athletes 
relied on biomarkers such as chromosomes. 
Officials dropped blanket testing in the 1990s, 
acknowledging that sex is irreducibly complex 
and that there is no scientific criterion for sepa-
rating all men from all women (6). Neverthe-
less, they retained an ad hoc policy for when a 
woman’s sex was questioned, which was criti-
cized for continuing the doomed project of sex 
testing and for being arbitrary (7).  
Still determined to find a biological way to 
regulate who can compete as a woman, policy 
makers turned to testosterone, arguing that T is 
both the “performance enhancing hormone” 
(8) and a sharply differentiated trait between 
men and women (2,3). In most studies, men’s 
T levels are about ten times that of women, and 
the highest levels seen in women are well be-
low the lowest levels seen in healthy men. One 
policy-maker characterized this as “a huge no 
man's land” (9).  
Policymakers have repeatedly stressed that: 
“there is no overlap between testosterone blood 
levels in healthy men and women” (2). Recent-
ly, though, the idea of unequivocal sex dimor-
phism in T levels has been challenged, at least 
in elite athletes. 
Only two large-scale studies of T in elite 
athletes exist, and they draw contradictory con-
clusions regarding a sex gap in T (10, 11). The 
first published study analyzes data from 446 
men and 234 women across 15 highly varied 
Olympic events (10). These data were collect-
ed as part of the GH-2000 study, an IOC- and 
World Anti-Doping Agency-funded project 
aimed at developing a test to detect human 
growth hormone abuse. The GH-2000 data 
show that “hormone profiles from elite athletes 
differ from usual reference ranges” in both men 
and women (10, p. 1). In fact, there was “over-
lap between men and women, although the 
mean values differ”. Among women, 13.7% 
had T above the typical female range, and 
4.7% were within the typical male range. In 
contrast to clinical reference ranges, 16.5% of 
these elite male athletes had T below the typi-
cal male range, with 1.8% falling in the female 
reference range. 
Not long after the GH-2000 report ap-
peared, IAAF researchers published their own 
study on serum T in 849 elite women athletes 
in track and field from the 2011 Daegu World 
Championships (11). That study showed just 
1.5% of women athletes with T above the fe-
male reference range, a sharp contrast with the 
13.7% in the GH-2000 study.  
 
DEBATING THE EVIDENCE. Three cri-
tiques of the GH-2000 report raised by IAAF 
policymakers in the Daegu study and in an 
IAAF/IOC rebuttal bear on whether there is a 
sex gap in T (11, 12). The first issue is how se-
ra were analyzed: the GH-2000 study used 
immunoassay (IA), while the Daegu study 
used mass spectrometry (MS). IA overesti-
mates T at lower values, which may partly ex-
plain the discrepancy between the studies in 
terms of the proportion of women athletes who 
show T levels above the reference range. There 
is no question that MS yields more accurate T 
readings at lower values. However, IA would 
overestimate T in anyone with low levels—
male or female. When the focus is simply on 
women with high T, the argument over method 
might seem reasonable because some women’s 
true values would be lower than were reported. 
But the overlap in men’s and women’s T levels 
isn’t simply the result of some women with 
high levels: a considerable proportion of men 
have low levels. If anything, the use of IA 
would understate the proportion of men with 
very low levels of T. So the use of IA cannot 
account for the finding of a male-female over-
lap in the GH-2000 data. The Daegu study did 
not report men’s values, so it can only shed 
partial light on the question of a gap. 
The second disagreement concerns when to 
draw serum because T changes in response to 
competition. Citing evidence that men’s T falls 
while women’s may stay the same or rise just 
after competition, IAAF/IOC policymakers 
suggest that the female-male overlap in T ob-
served in the GH-2000 data may be an artifact 
of drawing samples within two hours after 
competition (12).  
This criticism requires a selective reading 
of the evidence on the effect of competition on 
T levels. The IAAF/IOC critique cites a single 
report showing male T levels dropped and fe-
male levels were steady or modestly rose after 
an Ironman competition (13). The broader lit-
erature, though, shows that T may rise, fall, or 
remain unchanged after competition, and the 
main factors determining the response seem to 
be the type and duration of competition, not 
sex (14, 15). Intense resistance exercise and 
exercise of shorter duration are associated with 
increase in T, whereas endurance exercise (es-
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pecially lasting greater than 3 hours) is associ-
ated with decrease in T (14, 15). There are few 
data on endogenous T in women athletes, but 
the most recent review again indicates a great 
variety of responses to exercise are possible —
including a large and lasting increase in resting 
T from long-term resistance training (14). 
The timing of serum collection in the GH-
2000 study makes sense in the anti-doping 
context, reflecting: “a need to clarify hormone 
profiles that may be expected to occur after 
competition when anti-doping tests are usually 
made” (10). Doping tests are often how wom-
en with high natural T are flagged, so under-
standing the response of natural T to competi-
tion is particularly important.  
The tussle over timing may obscure the 
important point that T is dynamic. Recent re-
search shows that, in both sexes, T dramatical-
ly responds to physical situations as well as so-
cial cues and contexts, diurnal rhythms, 
training, and other factors (14–17). For exam-
ple, positive feedback from a coach can cause 
a rapid doubling of T level (though there is 
great variation among individuals) (17). Thus 
there is no universally correct time to sample 
T—it depends upon the purpose of the study. 
As with the choice of IA versus MS, the timing 
of blood draws is unlikely to account for the 
presence or absence of an overlap in T be-
tween the sexes. 
The third issue raised by the IOC/IAAF 
critiques of the GH-2000 study is the most 
fundamental: the rules for subject inclusion 
and exclusion. Both scientific groups agree 
that subjects who have doped should be ex-
cluded. Where they part is whether women 
with naturally high T should be excluded.  
The two camps take opposite views on 
whether to include these women—a decision 
that bears directly on whether their findings 
support or undermine the policies. The GH-
2000 study includes all women with high natu-
ral T in the sample. The Daegu study included 
women with high T of unknown etiology, but 
excluded as “confounding factors” all women 
whose high natural T can be traced to Diverse 
Sex Development, also known as Intersex 
(DSDI). In simplest terms, women with DSDI 
have some biological characteristics that would 
be classified as female and others that would 
be classified as male. This challenges common 
ideas about sex, but it is widely recognized in 
medicine, law, and the social sciences that 
when people are born with mixed markers of 
sex (e.g., chromosomes, genitals, gonads), the 
medical standard is that gender identity is the 
definitive marker of sex—–there is no better 
criterion (18). 
What, then, is the logic that classifies 
women with DSDI as confounders? The Dae-
gu report consistently pairs clinical language 
such as  “diagnosis” and “disorder” with hy-
perandrogenism for the women with DSDI, 
and in their rebuttal to the GH-2000 paper, 
IAAF/IOC policy makers use the phrase “hy-
perandrogenic disorders of sex development” 
(12). This signals their judgment that women 
with DSDI are not healthy, and therefore 
should be excluded from reference ranges. But 
DSDI women aren’t necessarily unhealthy. 
High T can be associated with health issues, 
but is not in and of itself a health problem for 
women (4).  
An a priori understanding of women with 
DSDI as unhealthy and thus outside normal 
variation creates a rationale for their exclusion 
both in reference ranges and the policies. But 
it’s also circular: because women with DSDI 
are a priori excluded when the reference rang-
es are created, the findings from the Daegu 
study—that women athletes have T no differ-
ent from non-athlete women—reinforces their 
values as outsiders and justifies the policy. 
There is a strong scientific argument for in-
cluding DSDI women in the sample. These 
studies aim to establish T reference ranges for 
elite athletes: i.e., the focus is on physiological 
ranges, not clinical ranges. This calls for de-
scriptive statistics, and in this case, there’s no 
valid basis for discarding some values as outli-
ers. In both studies, if the full range of values 
for women’s endogenous T is included, there is 
an overlap in T. 
 
CALCULATING FAIRNESS. What looks 
like a controversy rooted firmly in science is 
ultimately a social and ethical one concerning 
how we understand and frame human diversi-
ty. These assessments are not trivial: they 
shape not only the research methods and find-
ings, but also how we understand what is at 
stake in this policy. And this has very real con-
sequences for people’s lives.  
Policymakers, among others, claim the 
problem is that women with naturally high T 
have unfair advantage despite acknowledging 
in their Daegu study that “there is no clear sci-
entific evidence proving that a high level of T 
is a significant determinant of performance in 
female sports” (11).   
Others see a very different problem: that 
women who have lived and competed as wom-
en their whole lives suddenly find themselves 
having to undergo medical interventions in or-
der to remain eligible to compete in a category 
to which everyone agrees they belong.  
Calculating what counts as a fair and level 
playing field for women must take all women 
athletes into account, including those with nat-
urally high T and/or DSDI. We could return to 
a consensus reached decades ago, where poli-
cymakers faced these same concerns and con-
cluded that women “who were raised as girls 
and classify themselves as female should not 
be excluded from competition as women” (19). 
In other words, ensuring that women with high 
endogenous T and/or DSDI “have the same 
rights to participation in athletics as all wom-
en” (20) would be a good place to start.   
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